Q1 EPS Estimate for Allogene Therapeutics Boosted by Analyst

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Stock analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for Allogene Therapeutics in a report issued on Tuesday, April 14th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.19) per share for the quarter, up from their previous forecast of ($0.24). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Allogene Therapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.66) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.08.

A number of other equities research analysts have also weighed in on the stock. Robert W. Baird raised their price target on shares of Allogene Therapeutics from $7.00 to $9.00 and gave the company an “outperform” rating in a report on Tuesday. Truist Financial upgraded shares of Allogene Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Canaccord Genuity Group restated a “buy” rating and set a $14.00 target price on shares of Allogene Therapeutics in a research note on Friday, March 13th. Sanford C. Bernstein lifted their target price on Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a research report on Tuesday. Finally, Jefferies Financial Group boosted their price target on Allogene Therapeutics from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.44.

Allogene Therapeutics Stock Up 9.2%

ALLO opened at $2.37 on Thursday. The firm’s 50 day moving average is $2.33 and its 200-day moving average is $1.72. Allogene Therapeutics has a 52-week low of $0.86 and a 52-week high of $4.46. The firm has a market capitalization of $577.76 million, a P/E ratio of -2.72 and a beta of 0.53.

Insider Activity at Allogene Therapeutics

In other news, SVP Earl Martin Douglas sold 22,900 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $1.76, for a total value of $40,304.00. Following the sale, the senior vice president owned 564,948 shares in the company, valued at approximately $994,308.48. This represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David D. Chang sold 95,269 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.80, for a total transaction of $171,484.20. Following the transaction, the chief executive officer directly owned 5,185,862 shares in the company, valued at $9,334,551.60. The trade was a 1.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 278,452 shares of company stock valued at $534,053. 13.20% of the stock is owned by insiders.

Institutional Trading of Allogene Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ALLO. Savant Capital LLC bought a new position in Allogene Therapeutics during the 3rd quarter worth approximately $27,000. Russell Investments Group Ltd. raised its position in shares of Allogene Therapeutics by 11,159.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company’s stock valued at $27,000 after acquiring an additional 21,650 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Allogene Therapeutics during the 3rd quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd lifted its stake in Allogene Therapeutics by 5,267.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company’s stock worth $30,000 after purchasing an additional 23,599 shares during the last quarter. Finally, Brighton Jones LLC boosted its holdings in Allogene Therapeutics by 81.6% in the third quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock worth $31,000 after purchasing an additional 11,311 shares during the period. Institutional investors and hedge funds own 83.63% of the company’s stock.

Key Allogene Therapeutics News

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: HC Wainwright raised quarterly and full‑year EPS forecasts, reiterated a “Buy” rating and a $12 price target — analysts trimmed loss expectations for 2026, signaling improved near‑term operational outlooks. HC Wainwright Research Note
• Positive Sentiment: Jefferies bumped its price target to $10 and kept a Buy rating, and Robert W. Baird raised its target to $9 — multiple broker upgrades lift sentiment and create momentum for upside expectations. Jefferies/Price Target Coverage
• Positive Sentiment: Allogene published preclinical data for ALLO‑329 in Nature Communications (dual CD19/CD70 allogeneic CAR‑T for autoimmune disease), a validation point for pipeline breadth outside oncology that can support longer‑term value. ALLO-329 Nature Communications Publication
• Neutral Sentiment: High volume of investor call purchases reported recently, indicating speculative/leveraged bullish interest that can amplify moves but is not a guarantee of fundamental improvement. Options Volume Report
• Negative Sentiment: Allogene closed an underwritten offering that raised ~$200.4M (87.5M shares at $2.00 plus option exercise). While the proceeds extend runway for trials and R&D, the large issuance is dilutive and has been cited as the catalyst for recent selloffs. Offering Closing Press Release
• Negative Sentiment: Unusual put-option activity and reports that the stock fell sharply after the equity raise indicate some investors are hedging or taking bearish positions tied to dilution and execution risk. Market Reaction to Equity Raise

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.